Accellix News
11 articles
Accellix Expands its Leadership Team
Accellix, the Cell Therapy QC Company Raises $9.5 Million Series D Round
Accellix, Inc. Announces Their Next Generation Accellix Instrument and Consumable to Further Simplify and Automate the QC Workflow in Cell Therapy Manufacturing
Accellix, Inc. Announces the Appointment of Nir Nimrodi as Chairman and Chief Executive Officer. Nimrodi Will Lead the Company's Accelerated Growth as It Launches Custom and Standardized Panel Assays to Be Used by Its Expanding Installed Base.
Accellix, Inc. Announces the Appointment of Nir Nimrodi as Chairman and Chief Executive Officer. Nimrodi Will Lead the Company's Accelerated Growth as It Launches Custom and Standardized Panel Assays to Be Used by Its Expanding Installed Base.
Orgenesis Announces Co-Development Agreement with Accellix
Orgenesis Inc. has entered into a co-development agreement with Accellix, Inc. to integrate Accellixs proprietary optic system, cartridges, reagents, and software into Orgenesis Point of Care cellular therapy processing services and platform. The integration aims to advance Orgenesis quality control systems. The financial details of the agreement were not disclosed. Orgenesis POCare platform is designed to collect, process, and supply cells within the patient care location for therapeutic treatments. The Accellix assay delivery platform enhances the quality control aspects of Orgenesis POCare platform. The partnership is expected to lower costs and bring autologous therapies to patients in a cost-effective, high-quality, and scalable manner.
Partners
Accellix, Inc Expands Leadership Team and Announces Name Change
Emosis and Accellix Announce Intent to Form a Joint Venture, EmoCellix
Emosis and Accellix have signed a letter of intent to form a joint venture called EmoCellix. The joint venture will focus on marketing a complete solution for hemostasis cytomolecular diagnostics. EmoCellix will integrate Emosis novel hemostasis cytomolecular diagnostic tests with Accellixs innovative assay delivery platform. The joint venture aims to provide a complete solution for on-demand point-of-care hemostasis and thrombosis diagnostics. Emosis and Accellix will each own 50% of the joint venture. Customers will still have the option to purchase non-integrated products and services from both companies.
Partners
http://www.marketwired.com/press-release/leukodx-ge-healthcare-enter-agreement-explore-solutions-cell-characterization-cell-therapy-2106534.htm
The article does not provide any information about a specific company or event.
LeukoDx Inc. Closes $7M Financing Round;Appoints Seymour Liebman & Mark Chess to BOD
LeukoDx Inc. has secured $7 million in new financing from Axcel Partners and individual investors. The funding will be used to accelerate the companys plans to bring the Accellix platform and rapid sepsis test to market. LeukoDx has also appointed Mark Chess and Seymour Liebman to serve as members of the Board of Directors. The companys mission is to deliver cost-effective, highly sensitive, and actionable diagnostic information at the point of care through its automated IVD flow cytometry platform. The Accellix platform and the Accellix Rapid Sepsis test are the companys first applications.
Investment
LeukoDx Closes $1.6M Financing Tranche, Inks Agreements for up to $8M
LeukoDx has secured commitments of up to $8 million in investments to develop its point-of-care platform for delivering flow cytometry in vitro diagnostic results. The initial $1.6 million tranche has been closed, and the remaining investment will depend on reaching certain milestones within the next two years. The company is also developing an assay for CD64 neutrophil activation under a licensing deal with Trillium Diagnostics, which will allow for rapid clinical diagnosis in various patient settings. LeukoDx is seeking partnerships with biotechnology and IVD companies to expand the menu for its platform.
InvestmentPartners
